LifeArc Ventures
Investor profile
Government / publicVenture capital
Also recorded as: LifeArc
Deals
8
distinct rounds
Companies
7
backed
Active span
2021–2026
6 yrs
Total round €
€275M
sum of rounds joined
Deals by year
distinct rounds / yearTop sectors
by dealsStages
by dealsCountries
by dealsCo-investment network
shared roundsHover a node for shared-deal counts; click a co-investor to open its profile.
Frequent co-investors
shared rounds- BGF3
- Monograph Capital2
- 5AM Ventures1
- Agent Capital1
- Ananda Impact Ventures1
- Andera Partners1
- Bristol Myers Squibb1
- British Patient Capital1
- Cambridge Angels1
- Carma Fund1
- Catalio Capital Management1
- Clarendon Fund Managers Limited1
- Crista Galli Ventures1
- Dementia Discovery Fund1
- Downing Ventures1
- Eka Ventures1
- Eli lilly and company1
- EQT Life Sciences1
- Fountain Healthcare Partners1
- General Catalyst1
- GIMV1
- IQ Capital1
- LBBW Venture Capital GmbH1
- Longwall Ventures1
- MegaRobo Technologies1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| GlycoEra | Switzerland | 1 | €114M |
| Maxion Therapeutics | UK | 2 | €81M |
| Exciva | Germany | 1 | €51M |
| Closed Loop Medicine | UK | 1 | €15M |
| Cumulus Neuroscience | Ireland | 1 | €7.0M |
| Oxcan | UK | 1 | €3.4M |
| Surgery Hero | UK | 1 | €2.9M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| GlycoEra | Series B | €114M | 2025-05 |
| Maxion Therapeutics | Series A | €66M | 2025-03 |
| Exciva | Series B | €51M | 2026-01 |
| Closed Loop Medicine | Series A | €15M | 2021-11 |
| Maxion Therapeutics | Series A | €15M | 2023-02 |
| Cumulus Neuroscience | Other | €7.0M | 2021-05 |
| Oxcan | Other | €3.4M | 2023-01 |
| Surgery Hero | Seed | €2.9M | 2022-11 |